Cord Blood Banking Market Projected to Reach $49.85B
The global market for cord blood banking services is projected to become a $49.85 billion opportunity by 2031, according to a report from Mordor Intelligence. Market growth is being driven by advancements in stem cell therapies, expanding applications in treating disorders, and rising awareness of preservation. North America currently leads the market, holding a nearly 40% share.
The concept of using umbilical cord blood dates back to the 1970s, but the first successful transplant occurred in 1988 in Paris. A five-year-old boy with the genetic disorder Fanconi Anemia was treated using stem cells from his newborn sister's umbilical cord. The first public cord blood bank was established in New York in 1992, creating an inventory for anyone in need. This was followed by the first private bank at the University of Arizona the same year, offering "biological insurance" for families. Today, there are over 800,000 units in public banks and more than 5 million samples in private storage. Families can choose between public donation, which is free and makes the cells available to any matching patient, or private banking for exclusive family use. Private banking involves an initial collection fee of up to $2,300 and annual storage fees that can cost several hundred dollars. Retrieving a unit from a public bank for transplant can cost approximately $45,000. Hematopoietic stem cells from cord blood can treat over 80 diseases, including cancers like leukemia, blood disorders such as sickle cell anemia, and some immune system deficiencies. These stem cells are immunologically immature, which can reduce the risk of complications like graft-versus-host disease compared to bone marrow transplants. The U.S. Food and Drug Administration (FDA) regulates banked cord blood. In April 2023, the FDA approved a new method for multiplying the number of stem cells from a cord blood unit, potentially expanding treatment options for adults and children. Beyond established treatments, clinical trials are exploring the use of cord blood in regenerative medicine for conditions like cerebral palsy, autism, and brain injuries.
